Opiant Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
September 24, 2019 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Pharmaceuticals Strengthens Management Team with Appointments of Chief Commercial Officer and General Counsel
September 17, 2019 08:00 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Pharmaceuticals Announces Presentations at Two Upcoming Investor Conferences
August 27, 2019 16:30 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 08, 2019 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Pharmaceuticals to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, August 8
July 30, 2019 16:30 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Pharmaceuticals Expands Partnership with Sanofi, Signs Agreement for Manufacturing OPNT004 for Treatment of Acute Cannabinoid Overdose
July 23, 2019 08:00 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today...
Opiant Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 09, 2019 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, May 9
April 30, 2019 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug...
Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT003, Nasal Nalmefene, for Treatment of Synthetic Opioid Overdose
April 08, 2019 08:00 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today...
Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT002, Nasal Naltrexone, for Treatment of Alcohol Use Disorder
April 03, 2019 08:00 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today...